论文部分内容阅读
目的观察心房颤动(房颤)患者使用华法林抗凝治疗的可行性及安全性。方法将80例老年房颤患者随机分为观察组和对照组各40例。在恢复和维持窦性心律的基础上,观察组使用法华林治疗,3mg/d口服,根据国际标准化比值(INR)调整剂量;对照组使用阿司匹林治疗,200mg/d口服。观察并记录2组患者INR值及血栓栓塞、出血等事件。结果观察组华法林维持量(1.75～4.75)mg/d,平均剂量(2.00±0.75)mg/d,INR值为3.08±0.72。2组出血发生率相似(P>0.05);血栓栓塞事件发生率观察组明显低于对照组(2.5%vs20.0%,P<0.05)。结论在严密监控INR情况下,使用华法林治疗房颤安全、可靠、效果好。
Objective To observe the feasibility and safety of warfarin anticoagulation in patients with atrial fibrillation (AF). Methods Eighty elderly patients with atrial fibrillation were randomly divided into observation group and control group, 40 cases each. On the basis of restoring and maintaining sinus rhythm, the observation group was treated with Fahrenheit at a dose of 3 mg / d orally, and the dose was adjusted according to the international normalized ratio (INR). The control group was treated with aspirin at 200 mg / d orally. Observed and recorded two groups of patients INR value and thromboembolism, bleeding and other events. Results The warfarin maintenance dose (1.75-4.75) mg / d, mean dose (2.00 ± 0.75) mg / d and INR value 3.08 ± 0.72.2 in the observation group were similar (P> 0.05). The thromboembolic events The incidence of observation group was significantly lower than the control group (2.5% vs20.0%, P <0.05). Conclusion In the close monitoring of INR, the use of warfarin in the treatment of atrial fibrillation is safe, reliable and effective.